Advertisement
Advertisement
ENTA
Enanta Pharmaceuticals, Inc
14.03
USDSponsored
+0.08
+0.58%
Mar 11, 14:40 UTC -4
Open
ENTA Earnings Reports
Positive Surprise Ratio
ENTA beat 26 of 40 last estimates.
65%
Next Report
Date of Next Report
May 11, 2026
Estimate for Q2 26 (Revenue/ EPS)
$17.43M
/-$0.49
Implied change from Q1 26 (Revenue/ EPS)
-6.35%
/+16.67%
Implied change from Q2 25 (Revenue/ EPS)
+16.80%
/-53.77%
Enanta Pharmaceuticals, Inc earnings per share and revenue
On Feb 09, 2026, ENTA reported earnings of -0.42 USD per share (EPS) for Q1 26, beating the estimate of -0.82 USD, resulting in a 49.01% surprise. Revenue reached 18.61 million, compared to an expected 16.46 million, with a 13.07% difference. The market reacted with a +2.17% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 6 analysts forecast an EPS of -0.49 USD, with revenue projected to reach 17.43 million USD, implying an increase of 16.67% EPS, and decrease of -6.35% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Septerna, Inc. Common Stock
Report Date
Mar 09, 2026 For Q4 25
Estimate
-$0.25
Actual
-$0.24
Surprise
+7.26%
ADC Therapeutics SA
Report Date
Mar 10, 2026 For Q4 25
Estimate
-$0.27
Actual
-$0.04
Surprise
+85.39%
Kamada Ltd
Report Date
Mar 11, 2026 For Q4 25
Estimate
$0.07
Actual
$0.06
Surprise
-24.15%
Coherus Oncology, Inc. Common Stock
Report Date
Mar 09, 2026 For Q4 25
Estimate
-$0.35
Actual
-$0.34
Surprise
+2.91%
Cartesian Therapeutics, Inc. Common Stock
Report Date
Mar 09, 2026 For Q4 25
Estimate
-$0.87
Actual
-$3.57
Surprise
-310.16%
Anixa Biosciences, Inc.
Report Date
Mar 09, 2026 For Q1 26
Estimate
-$0.09
Actual
-$0.08
Surprise
+17.44%
Spruce Biosciences, Inc. Common Stock
Report Date
Apr 13, 2026 For Q4 25
Estimate
-$8.14
Actual
-Surprise
-
BioNTech SE - ADR
Report Date
Mar 10, 2026 For Q4 25
Estimate
-$0.18
Actual
-$0.32
Surprise
-72.12%
Legend Biotech Corporation - ADR
Report Date
Mar 10, 2026 For Q4 25
Estimate
-$0.11
Actual
-$0.08
Surprise
+27.73%
Briacell Therapeutics Corp. Common Shares
Report Date
Mar 10, 2026 For Q2 26
Estimate
-$4.88
Actual
-$2.58
Surprise
+47.22%
FAQ
What were Enanta Pharmaceuticals, Inc's earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, Enanta Pharmaceuticals, Inc reported EPS of -$0.42, beating estimates by 49.01%, and revenue of $18.61M, 13.07% above expectations.
How did the market react to Enanta Pharmaceuticals, Inc's Q1 2026 earnings?
The stock price moved up 2.17%, changed from $13.83 before the earnings release to $14.13 the day after.
When is Enanta Pharmaceuticals, Inc expected to report next?
The next earning report is scheduled for May 11, 2026.
What are the forecasts for Enanta Pharmaceuticals, Inc's next earnings report?
Based on 6
analysts, Enanta Pharmaceuticals, Inc is expected to report EPS of -$0.49 and revenue of $17.43M for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement